These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1434 related items for PubMed ID: 32333236

  • 1. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S.
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [Abstract] [Full Text] [Related]

  • 2. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
    Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, Cui LQ, Wang AH.
    Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
    [Abstract] [Full Text] [Related]

  • 3. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H.
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [Abstract] [Full Text] [Related]

  • 4. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y, Ma X, Zheng J, Jia J, Yan T.
    BMC Nephrol; 2017 Jun 30; 18(1):206. PubMed ID: 28666408
    [Abstract] [Full Text] [Related]

  • 5. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH.
    Lancet Oncol; 2011 Jan 30; 12(1):65-82. PubMed ID: 21123111
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L, Zeng X, Fu P, Wu HM.
    Cochrane Database Syst Rev; 2014 Jun 23; 2014(6):CD009120. PubMed ID: 24953826
    [Abstract] [Full Text] [Related]

  • 7. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Oct 27; 10(10):CD007004. PubMed ID: 33107592
    [Abstract] [Full Text] [Related]

  • 8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J.
    JAMA Intern Med; 2014 May 27; 174(5):773-85. PubMed ID: 24687000
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC, Wu YT, Yang WC, Tsai MJ, Liu JS, Yang CY, Li SY, Ou SM, Tarng DC, Hsu CC.
    PLoS One; 2017 May 27; 12(12):e0189126. PubMed ID: 29216260
    [Abstract] [Full Text] [Related]

  • 10. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.
    JAMA Intern Med; 2014 Mar 27; 174(3):347-54. PubMed ID: 24343093
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007751. PubMed ID: 21975774
    [Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
    Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL.
    BMJ; 2013 Oct 24; 347():f6008. PubMed ID: 24157497
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 24; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
    Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH.
    Mayo Clin Proc; 2016 Jan 24; 91(1):51-60. PubMed ID: 26763511
    [Abstract] [Full Text] [Related]

  • 15. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM.
    Cochrane Database Syst Rev; 2015 Jan 11; 1():CD008170. PubMed ID: 25577154
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.
    Hu Y, Liang L, Liu S, Kung JY, Banh HL.
    J Clin Hypertens (Greenwich); 2023 Aug 11; 25(8):661-688. PubMed ID: 37417783
    [Abstract] [Full Text] [Related]

  • 17. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS, Cheng YM, Zeng XX, Kim S, Fu P.
    Chin Med J (Engl); 2016 Mar 05; 129(5):562-9. PubMed ID: 26904991
    [Abstract] [Full Text] [Related]

  • 18. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R, Rios P, Baldovinos G, Chichet MA, Perg N, Sola L, Saona G, De Souza N, Lamadrid V, Gadola L.
    Nephron; 2019 Mar 05; 143(2):100-107. PubMed ID: 31203280
    [Abstract] [Full Text] [Related]

  • 19. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, Li J, Zhang J, Xu Y, Lu H, Xu D.
    BMC Cardiovasc Disord; 2017 Oct 05; 17(1):257. PubMed ID: 28982370
    [Abstract] [Full Text] [Related]

  • 20. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
    Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J.
    Diabetologia; 2012 Mar 05; 55(3):566-78. PubMed ID: 22189484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.